Patents by Inventor Rama Mukherjee

Rama Mukherjee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6608174
    Abstract: The present invention encompasses radiolabeled peptide analogs of vasoactive intestinal peptide (VIP) labeled with a radionuclide useful for imaging target sites within mammalian living systems. The invention particularly provides radiolabeled VIP derivatives that bind selectively to the VIP receptor on target cells. Specifically, the invention relates to the radiolabeling of VIP-receptor specific agents and their subsequent use for radiodiagnostic and radiotherapeutic purposes. The invention encompasses methods for radiolabeling these peptides with radio-nuclides and the use of these peptides as scintigraphic imaging agents.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: August 19, 2003
    Assignee: Dabur Research Foundation
    Inventors: Anand C. Burman, Sudhanand Prasad, Rama Mukherjee, Sarjana Dutt, Rajan T. Sharma, Rinku Ahuja, Anil K. Mishra, Lazar T. Mathew
  • Patent number: 6596692
    Abstract: The present invention encompasses novel synthetic peptide analogs that are antagonists to Substance P, substance P like peptides and related peptides and are useful for the treatment of cancer. The invention particularly relates to the design and synthesis of the novel substance P antagonist analogs incorporating &agr;,&agr;-dialkylated amino acids in a site specific manner. The invention encompasses methods for the generation of these peptides, compositions containing these peptides and pharmacological applications of these peptides specifically in the treatment and prevention of cancer.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: July 22, 2003
    Assignee: Dabur Research Foundation
    Inventors: Anand C. Burman, Sudhanand Prasad, Rama Mukherjee, Manu Jaggi, Anu T. Singh
  • Patent number: 6596755
    Abstract: The invention relates to an oral formulation of methylglyoxal and/or its imino acid conjugates for human use and methods for preparing the compositions. Particularly, the invention relates to compositions comprising methylglyoxal and more particularly, imino acid conjugates of methylglyoxal. The present invention also relates to formulations of methylglyoxal and imino acid conjugates of methylglyoxal that can be used for the treatment and suppression of malignant diseases including but not limited to the cancers of Colon, Prostate, Pancreas, Lung, Oral cavity, Glioblastoma, and Leukemia.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: July 22, 2003
    Assignee: Dabur Research Foundation
    Inventors: Anand C. Burman, Rama Mukherjee, Dhiraj Khattar, Mukesh Kumar
  • Publication number: 20030118627
    Abstract: The invention relates to the use of imino acid conjugates of methylglyoxal for the inhibition and/or treatment of cancer. The invention relates more specifically to the use imino acid conjugates of methylglyoxal for inhibition and/or treatment of cancer of the Colon, Prostate, Larynx, Kidney, Pancreas, Lung, Breast, Intestine, Oral cavity, Ovary, Glioblastoma, and Leukemia. The invention also relates to compositions and methods of inhibiting cancer using imino acid conjugates of methylglyoxal.
    Type: Application
    Filed: July 1, 2002
    Publication date: June 26, 2003
    Applicant: DABUR RESEARCH FOUNDATION
    Inventors: Anand C. Burman, Rama Mukherjee, Manu Jaggi, Anu T. Singh, Kamal K. Kapoor, Sudhanand Prasad, Manju Ray
  • Publication number: 20030105009
    Abstract: A polypeptide of the formula (I),
    Type: Application
    Filed: June 28, 2002
    Publication date: June 5, 2003
    Applicant: DABUR RESEARCH FOUNDATION
    Inventors: Sudhanad Prasad, Rama Mukherjee, Anand C. Burman, Archna Mathur, Rajan Sharma, Manu Jaggi
  • Publication number: 20030087951
    Abstract: The invention relates to an oral formulation of methylglyoxal and/or its imino acid conjugates for human use and methods for preparing the compositions. Particularly, the invention relates to compositions comprising methylglyoxal and more particularly, imino acid conjugates of methylglyoxal. The present invention also relates to formulations of methylglyoxal and imino acid conjugates of methylglyoxal that can be used for the treatment and suppression of malignant diseases including but not limited to the cancers of Colon, Prostate, Pancreas, Lung, Oral cavity, Glioblastoma, and Leukemia.
    Type: Application
    Filed: July 1, 2002
    Publication date: May 8, 2003
    Applicant: DABUR RESEARCH FOUNDATION
    Inventors: Anand C. Burman, Rama Mukherjee, Dhiraj Khattar, Mukesh Kumar
  • Publication number: 20030082201
    Abstract: Multivalent vaccine comprising peptides from vasoactive intestinal peptide, bombesin, Substance P and epidermal growth factor are described. A method of constructing a multivalent gene for use in various expressions vectors and the protein recombinantly expressed in the prokaryotic expression systems are also described.
    Type: Application
    Filed: August 2, 2002
    Publication date: May 1, 2003
    Applicant: DABUR RESEARCH FOUNDATION
    Inventors: Rama Mukherjee, M.R.S. Rao, Arnand C. Burman, Becky Thomas, Sudhanand Prasad, Paromita Sengupta
  • Publication number: 20030050233
    Abstract: The present invention relates to a combination of peptides that may be used for treatment of cancer. The combination of peptides modulates multiple cellular pathways implicated in cell proliferation by altering the levels of key intracellular molecules thereby showing a broad spectrum of anticancer activity. The invention also relates to a pharmaceutical composition containing a combination of such peptide analogs.
    Type: Application
    Filed: June 29, 2001
    Publication date: March 13, 2003
    Applicant: DABUR ONCOLOGY PLC
    Inventors: Anand C. Burman, Rama Mukherjee, Sudhanand Prasad, Manu Jaggi, Anu T. Singh
  • Patent number: 6492330
    Abstract: The invention relates to the use of peptides individually or in combination, for treating and/or preventing angiogenesis. It also relates to the use of peptide analogs or a combination of peptides referred to as MuJ-7 as anticancer drugs in restricting the tumor growth and spread by inhibiting tumor angiogenesis. MuJ-7, in addition inhibits metastasis through its antiangiogenic activity in all cancers. The invention also relates to a pharmaceutical composition containing either individual peptides or in combination, and methods of treatment of human beings and animals for curing and/or preventing angiogenesis.
    Type: Grant
    Filed: February 11, 1999
    Date of Patent: December 10, 2002
    Assignees: National Institute of Immunology, Dabur Research Foundation
    Inventors: Rama Mukherjee, Manu Jaggi, Sudhanand Prasad, Anand C. Burman, Praveen Rajendran, Archana Mathur, Anu T. Singh
  • Patent number: 6489297
    Abstract: The present invention encompasses novel analogs of vasoactive intestinal peptide (VIP), containing substitutions at appropriately selected amino acids. The invention particularly relates to the design and synthesis of novel biologically active VIP analogs containing &agr;,&agr;-dialkylated amino acids in a site-specific manner. Specifically, the invention relates to the synthesis of VIP peptide derivatives, which bind selectively to VIP receptors on target cells.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: December 3, 2002
    Assignee: Dabur Research Foundation
    Inventors: Anand C. Burman, Sudhanand Prasad, Rama Mukherjee, Anu T. Singh, Archna Mathur, Neena Gupta
  • Publication number: 20020091091
    Abstract: The present invention provides compositions and methods for the solubilization of poorly soluble drugs such as triterpenes like betulinic acid and/its derivatives in pharmaceutically acceptable liquid vehicles that avoid use of potentially toxic solvents that are often used for the solubilization of poorly soluble drugs. In the compositions of this invention the drugs remain physically and chemically stable and can be administered intravascularly without undue toxicity from undissolved drug and/or from the solvent vehicles at a drug dose meant to be effective to exhibit clinically significant anticancer activity.
    Type: Application
    Filed: March 8, 2001
    Publication date: July 11, 2002
    Applicant: DABUR RESEARCH FOUNDATION
    Inventors: Anand C. Burman, Rama Mukherjee, Honey Bala, Dhiraj Khattar
  • Patent number: 6365191
    Abstract: This invention relates to pharmaceutical formulations of paclitaxel, its derivatives or analogs entrapped into nanoparticles of co-polymeric micelles, a process for preparing the same and the use thereof.
    Type: Grant
    Filed: September 21, 2000
    Date of Patent: April 2, 2002
    Assignee: Dabur Research Foundation
    Inventors: Anand C. Burman, Rama Mukherjee, Dhiraj Khattar, Mukesh Kumar, Honey Bala, Rajiv Kumar Shrivastava
  • Patent number: 6322817
    Abstract: This invention relates to pharmaceutical formulations of paclitaxel, its derivatives or analogs entrapped into nanoparticles of co-polymeric micelles, a process for preparing the same and the use thereof.
    Type: Grant
    Filed: September 23, 1999
    Date of Patent: November 27, 2001
    Assignees: Dabur Research Foundation, Delhi University
    Inventors: Amarnath Maitra, Sanjeeb Kumar Sahoo, Prasanta Kumar Ghosh, Anand C. Burman, Rama Mukherjee, Dhiraj Khattar, Mukesh Kumar, Soumendu Paul
  • Patent number: 6316414
    Abstract: The present invention encompasses novel peptides that are agonists to somatostatin and the use of the agonists for treatment of cancer. The invention particularly relates to the design and synthesis of novel analogs of somatostatin incorporating &agr;, &agr;-dialkylated amino acids in a site specific manner. The invention encompasses methods for the generation of these peptides, compositions containing the peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: November 13, 2001
    Assignee: Dabur Research Foundation
    Inventors: Anand C. Burman, Sudhanand Prasad, Rama Mukherjee, Manu Jaggi, Anu T. Singh, Archna Mathur
  • Patent number: 6156725
    Abstract: A pharmaceutical composition useful for killing or inhibiting multiplication of cancer cells. It is expected that the pharmaceutical composition will be useful in preventing, inhibiting, or modulating the hypersecretion of VIP, somatostatin, bombesin, Substance P, or a combination of VIP, somatostatin, bombesin, or Substance P. The composition may suitably comprise, consist of, or consist essentially of a therapeutically effective combination of peptide analogs of somatostatin, VIP, bombesin, and Substance P. Also provided is a method of treatment for humans or other animals suffering from cancer, the method comprising administering a therapeutically effective dose of the pharmaceutical composition so as to kill or inhibit the multiplication of cancer cells. The method of treatment may be particularly useful in the treatment of cancers of the colon and rectum.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: December 5, 2000
    Assignee: National Institute of Immunology
    Inventors: Rama Mukherjee, Manu Jaggi
  • Patent number: 5744363
    Abstract: The present invention provides a novel method for the establishment of tumorigenic cell lines from biopsies of human or animal tumors. The method includes preparing a single-cell suspension of a tumor cells by injecting cell culture medium into an isolated tumor or a portion thereof to flush out the tumor cells. The tumor or portion thereof may be in a cell culture maintenance medium. The step of injecting cell culture medium into the isolated tumor or portion thereof involves piercing the tumor or portion thereof with a needle to inject the cell culture medium and flush out the tumor cells. The steps of piercing the tumor or portion thereof with a needle and injecting the cell culture medium to flush out the tumor cells preferably are repeated until the single-cell suspension has a particular cell density. The method also includes establishing a primary tumor cell culture by growing the cells from the single-cell suspension in a cell culture medium.
    Type: Grant
    Filed: December 13, 1996
    Date of Patent: April 28, 1998
    Assignee: National Institute of Immunology
    Inventors: Rama Mukherjee, Manu Jaggi